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In a recent issue of Leukemia, Borowitz et al 1 have shown a significant correlation between surface expression of two Blineage antigens and rearrangements of the TEL gene in children with acute lymphoblastic leukemia (ALL). This lead authors to suggest that the patients who are screened by immunophenotypic features as TEL/AML1 negative may not be tested for TEL/AML1 fusion by reverse-transcriptase polymerase chain reaction (RT-PCR). Borowitz et al present new data that are important for studying biologic behavior of blasts with this favorable molecular genetic feature. However, we feel that the suggestion of using immunophenotypic features as a cost-effective pre-screening of patients predicted for TEL/AML1 negativity needs re-evaluation.
TEL/AML1-positive ALL is a clinically important subgroup of pediatric ALL. The patients with this chromosomal fusion account for 20 to 25% of children with ALL in the developed world. 2 Several prospective and retrospective studies have documented good prognosis for these patients. 3, 4 The majority of patients with TEL/AML1-positive ALL tend to cluster around the modus of the pre-school peak age; however, not the entire peak is formed by these patients. 5 Several studies reported that TEL/AML1-positive ALL are likely to express myeloid antigens CD13 and CD33. 2, 6, 7 Later, lack of expression of a granulocytic antigen KOR-SA3544 has been shown to predict TEL/AML1 negativity. 7 This antigen is up to now the most reliable predictor of TEL/AML1 negativity (Table 1) . Borowitz et al now add a combination of CD20 and CD9 to the list of antigens with a predictive value for TEL rearrangement (and hence for TEL/AML1 status). In addition to immunophenotypic features, hyperdiploidy is known to inversely correlate with the TEL/AML1 positivity. 1, 2, 6 Thus, TEL/AML1-positive ALL emerges as a disease with distinct clinical and immunophenotypic features. However, as Borowitz et al noted, none of the features predicts TEL/AML1 status in all patients (we have recently observed a TEL/AML1-positive patient with 12% KOR-SA3544-positive blasts at diagnosis thus proving that even this test has a negative predictive value less than 100%, Table 1 ).
What are the requirements for a pre-screening test for TEL/AML1 testing? Ultimate proof of a clinical usefulness would obviously be a requirement if the result of a predictive test per se has a high prognostic value for treatment outcome. Thus far, this has not been documented for any of the immunophenotypic features listed in Table 1 . To the contrary, CD13 and CD33 have been shown to have no clinical impact in large cohorts. 8 The criteria for a pre-screening method would be: (1) high and reproducible negative predictive value; and (2) low cost and labor intensity of the method when compared to RT-PCR for TEL/AML1. The first of the two criteria is not successfully met by any of the immunophenotypes: while CD13 and CD33 do not have a very high negative predictive value, KOR-SA3544 antigen as well as combination of CD9 and CD20 have been only reported from single studies. Although we observed a tendency of CD20-positive cases to be TEL/AML1-negative, this difference was not significant in our cohort (unlike in the study by Borowitz et al
. Thus, the choice of a monoclonal antibody clone and conjugate and perhaps the subjective distinction of 'CD20-positive' from 'CD20-partially positive' cases might be important to be able to reproduce the data of Borowitz et al at the same level of significance. For practical reasons, KOR-SA3544 seems to be superior to other phenotypes since a single molecule has a higher predictive value than combinations of molecules ( Table 1) .
The economic impact of any pre-screening of TEL/AML1 status is doubtful. We estimate that 80% of the cost for TEL/AML 1 testing in our laboratory is required for cDNA preparation. Since most ALL protocols require BCR/ABL and MLL/AF4 testing for risk stratification, cDNA would have to be prepared even for the patients who would be screened as 'TEL/AML1-negative'. Therefore, omitting the RT-PCR for TEL/AML1 in 57% patients, as Borowitz et al 1 suggested, would save only about 10% of total cost. This does not take into account the cost of the screening procedure; the net economic impact would therefore stay below 10%. We feel that at this point the loss of clinically important information on patients who are falsely pre-screened as TEL/AML1-negative would outweigh the overall potential benefit of the screening.
In conclusion, although the correlation between levels of CD9 and CD20 expression and TEL rearrangements provides novel and potentially biologically important data, CD9 and CD20 testing should not be considered for replacing TEL/AML1 testing for a proportion of patients. The economic impact of the pre-screening is questionable and the losses caused by falsely negative pre-screening may be unpredictably high. We suggest that even those immunophenotypes with a higher predictive value should not be used as pre-screening at this point.
